Last reviewed · How we verify

Anja Bisgaard Pinborg — Portfolio Competitive Intelligence Brief

Anja Bisgaard Pinborg pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
No Lutinus + transfer day 6 No Lutinus + transfer day 6 marketed monoamine oxidase inhibitor monoamine oxidase A and B Psychiatry
Lutinus + transfer day 6 Lutinus + transfer day 6 marketed Progesterone supplement Progesterone receptor Reproductive Medicine / Fertility
No Lutinus + transfer day 7 No Lutinus + transfer day 7 marketed Lipid-lowering agent Cardiovascular
Lutinus + transfer day 7 Lutinus + transfer day 7 marketed Progesterone supplement Progesterone receptor Reproductive Medicine / Fertility

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Breath of Life International Pharma Ltd · 1 shared drug class
  2. OmegaD LLC · 1 shared drug class
  3. Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Anja Bisgaard Pinborg:

Cite this brief

Drug Landscape (2026). Anja Bisgaard Pinborg — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/anja-bisgaard-pinborg. Accessed 2026-05-15.

Related